Navigation Links
New study reveals signaling pathways required for expansion of pancreas stem cells

IDDM, which used to be referred to as Type 1 diabetes, results from selective destruction of insulin-producing pancreatic islet beta cells by the body's immune system. Islet beta cells are spread throughout the pancreas and are made up of two types of cells: alpha cells, which make glucagon, a hormone that raises the level of glucose (sugar) in the blood, and beta cells, which make insulin.

The article appears in the May 12 issue of The Journal of Biological Chemistry.

"Our work focused on guiding stem cells, or pancreas progenitors, to differentiate into beta cells. This approach required that we increase the number of pancreas progenitors by finding the signals that cause them to proliferate. It also required that we understand the 'cues' that activate stem cells to turn into insulin-producing beta cells," says Nora Sarvetnick, Ph.D., a Scripps Research professor in the Department of Immunology.

The overall goal of this five-year study, funded by the National Institutes of Health, was to discover the roles of two proteins-BMP4 and Id-in causing proliferation or expansion of pancreatic progenitors. Hong Hua, a postdoctoral fellow in Sarvetnick's lab, was the lead author of this study.

The progression of pancreatic stem cells to beta cells is governed by the expression of key proteins, including a class of proteins called bHLH transcription factors that regulate gene expression. Ids (inhibition of differentiation factors) are a family of proteins implicated in a number of cellular processes, including cell proliferation. The major role of Id proteins is to bind to, and inhibit, the function of bHLH proteins, including those that are important in pancreas development. Therefore, Id proteins could bind to bHLH proteins in the developing pancreas and prevent them from differentiating into mature insulin-producing cells and, at the same time, cause them to proliferate.

"Interestingly, the expression of Id proteins is induced by b one morphogenetic proteins (BMPs) targets in another cell type," says Sarvetnick. "We wanted to know whether BMP can cause an increase of Id expression, and if this would result in proliferation of the stem cells."

Her work incorporated several techniques to test these hypotheses, including the use of pancreas progenitor AR42J cells and transgenic mouse models. The team's data demonstrated that BMP4 signaling is necessary and sufficient for proliferation of AR42J progenitor cells, and that this growth is correlated with an increase in Id expression. The group also did immunohistochemistry staining to show that BMP and Id proteins are found in abundance in the embryonic mouse pancreas, which contains proliferating stem cells.

A possible source of pancreatic progenitor cells is thought to derive from pancreas epithelial duct cells. The pancreas of the mouse model that the Sarvetnick lab used contains an abundance of regenerating stem cells from the ducts. "Importantly, we found that if we inject an antibody that inhibits BMP4 into these mice, this significantly reduced the number of proliferating duct cells. We also found that in these mice inhibition of BMP4 results in an increase in the expression of a bHLH protein-dependent factor PAX6, which is required for the final differentiation of pancreatic islet cells."

The group's results indicate that BMP4 stimulation blocks the differentiation of endocrine progenitor cells through induction of Id, which, in its dual role, promotes their expansion, revealing a novel paradigm of signaling that explains the balance between expansion and differentiation of pancreatic epithelial progenitors.

"The complications of diabetes mellitus impose enormous medical, economic, and social costs to both the patient and the health-care system. These experiments provide novel insights into the signaling pathways that are required for expansion of pancreas stem cells," says Sarvetnick. "Our work may provide a starting point toward improving the efficacy of treatments for patients and perhaps the prevention of clinical disease."

"It is not known to what extent replacement of insulin-producing cells occurs in the phase of diabetes when these cells are being actively eliminated," says Alberto Hayek, a professor of pediatrics at the University of California, San Diego and scientific director of the Whittier Institute for Diabetes. "The replacement may occur at the expense of self-replication of still-intact beta cells, or at the expense of replication and further differentiation of precursor cells into new endocrine cells. If these cells arise in the pancreatic ducts, as Dr. Sarvetnick's work has previously shown in animal models developed in her lab, the identification of the proteins (BMPs) described in this research is an important step for the potential application of therapies aimed at increasing a pool of cells that will become insulin-producing."


Source:Scripps Research Institute

Related biology news :

1. Bioartificial kidney under study at MCG
2. W.M. Keck Foundation funds study of friendly microbes
3. Yellowstone microbes fueled by hydrogen, according to U. of Colorado study
4. Genome-wide mouse study yields link to human leukemia
5. Clam embryo study shows pollutant mixture adversely affects nerve cell development
6. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
7. Same mutation aided evolution in many fish species, Stanford study finds
8. Sequencing of marine bacterium will help study of cell communication
9. Genetically modified rice in China benefits farmers health, study finds
10. A new study examines how shared pathogens affect host populations
11. NYU study reveals how brains immune system fights viral encephalitis
Post Your Comments:

(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... health pioneer, Joseph C. Kvedar , MD, describes ... wellness, and the business opportunities that arise from it ... Healthy Things . Long before health and wellness ... vice president, Connected Health, Partners HealthCare, was creating a ... the hospital or doctor,s office into the day-to-day lives ...
(Date:10/27/2015)... SAN JOSE, Calif. , Oct. 27, 2015 /PRNewswire/ ... human interface solutions, today announced that Google has adopted ... family of touch controller solutions to power its newest ... Nexus 6P by Huawei. --> ... ecosystem partners like Google to provide strategic collaboration in ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... Nev. , Nov. 24, 2015  PDL BioPharma, Inc. ... P. McLaughlin , the company,s president and chief executive officer, ... Healthcare Conference next week in New York City ... occur on Tuesday, December 1, 2015 at 9:30 a.m. EST. ... Please connect to the website at least 15 minutes prior ...
(Date:11/24/2015)... ... ... Laboratories is pleased to announce that it has completed construction on a new ... 61, USP 62 and USP 51 testing specific to raw materials and will enable ... by one supplier. Management has formally announced that the facility will be ...
(Date:11/23/2015)... CHICAGO , Nov. 24, 2015 Women with ... screening CT exams face a higher risk of lung cancer ... being presented next week at the annual meeting of the ... --> --> Lung ... are classified as solid or subsolid based on their appearance ...
(Date:11/23/2015)... KONG, Nov. 23, 2015 China Cord Blood ... China,s leading provider of cord blood collection, laboratory testing, ... today announced its preliminary unaudited financial results for the ... ended September 30, 2015. --> ... , Revenues for the second quarter of fiscal ...
Breaking Biology Technology: